Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337365 | 0.90 | TBXAS1 (0.36) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17337360 | 0.90 | TBXAS1 (0.36) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17337337 | 0.90 | TBXAS1 (0.39) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17337339 | 0.90 | TBXAS1 (0.39) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17337442 | 0.89 | TBXAS1 (0.40) | TBXAS1ROCK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL17337446 | 0.89 | TBXAS1 (0.40) | TBXAS1ROCK2ALDH1A1KDM4EMEN1 | |
| SCHEMBL17337151 | 0.89 | TBXAS1 (0.46) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17337153 | 0.89 | TBXAS1 (0.46) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL23837599 | 0.88 | TBXAS1 (0.37) | TBXAS1ROCK2ALDH1A1KDM4EAHR | |
| SCHEMBL17347848 | 0.88 | KDM4E (0.43) | TBXAS1ROCK2ALDH1A1KDM4EAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TBXAS1 1938/4885ROCK2 2893/4885ALDH1A1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.